Core Viewpoint - New Nuo Wei's stock price has shown fluctuations, with a year-to-date increase of 7.46% but a recent decline of 5.42% over the past five trading days, indicating volatility in investor sentiment and market performance [2]. Company Overview - New Nuo Wei, established on April 5, 2006, and listed on March 22, 2019, is based in Shijiazhuang, Hebei Province. The company specializes in the research, production, and sales of functional foods, with its main revenue sources being functional foods and raw materials (88.93%), biopharmaceuticals (8.91%), and others (2.16%) [2]. - The company operates within the pharmaceutical and biological sector, specifically in chemical pharmaceuticals and raw materials, and is associated with various concept sectors including large-cap stocks, margin financing, fund holdings, vitamins, and innovative drugs [2]. Financial Performance - For the period from January to September 2025, New Nuo Wei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%. However, the net profit attributable to shareholders was a loss of 24.0489 million yuan, a significant decrease of 117.26% compared to the previous year [2]. - Since its A-share listing, New Nuo Wei has distributed a total of 651 million yuan in dividends, with 500 million yuan distributed over the last three years [3]. Shareholder Structure - As of September 30, 2025, New Nuo Wei had 20,700 shareholders, a decrease of 15.05% from the previous period. The average number of circulating shares per shareholder increased by 17.72% to 67,930 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 17.7822 million shares (a decrease of 3.2169 million shares), and several mutual funds with varying changes in their holdings [3].

Market Overview - The A-share market exhibited a mixed performance last week, with major indices showing varied results: CSI 300 down 0.57%, CSI 500 up 2.18%, CSI 1000 up 1.27%, ChiNext 50 up 0.80%, and Sci-Tech 50 up 2.58% [1][10] - The average daily trading volume in the A-share market was approximately 3.4 trillion yuan, indicating high investor enthusiasm [1][10] - Key market hotspots included AI applications, commercial aerospace, controllable nuclear fusion, AI healthcare, power grid equipment, computing hardware, tourism and hotels, and non-ferrous metals, showcasing rapid rotation and localized activity [1][10] Investment Recommendations - It is suggested to focus on sectors supported by policy and experiencing a rebound in sentiment, particularly growth assets with performance backing, such as those in AI applications and AI healthcare [1][10] ChiNext 50 Index Insights - The ChiNext 50 Index serves as a direct financing platform for innovative and entrepreneurial companies, focusing on "three innovations (innovation, creation, creativity)" and "four new (new technologies, new industries, new business formats, new models)" [1][10] - The index emphasizes four key sectors: information technology, new energy, financial technology, and pharmaceuticals, reflecting a pure technology growth attribute [1][10] Sector Analysis Technology, AI, and Communication - The ChiNext 50 Index includes 52% of the information technology sector, with a recent surge in AI applications [3][12] - Notable developments include Alibaba's new Qianwen App integrating with its ecosystem for a seamless shopping experience and OpenAI's announcement of testing advertising features in the U.S. [3][12] - The long-term outlook for AI models and ecosystem collaboration is expected to open new commercial avenues, with increasing penetration in e-commerce, healthcare, and manufacturing [3][12] New Energy and Photovoltaics - The power equipment sector received significant positive news as the State Grid announced a projected fixed asset investment of 4 trillion yuan during the 14th Five-Year Plan, a 40% increase from the previous plan [4][12] - The Ministry of Industry and Information Technology emphasized accelerating breakthroughs in solid-state battery technology, with multiple companies investing in related materials [4][12] - The substantial investment by the State Grid is anticipated to enhance new energy consumption capacity, leading to a potential explosion in new energy installations [4][12] Pharmaceuticals and Biotechnology - The recent JPM Healthcare Conference highlighted several Chinese pharmaceutical companies, showcasing their R&D and operational progress to the international market [5][14] - The innovative drug sector is experiencing multiple catalysts, including corporate collaborations and advancements in technology, which are boosting market sentiment [5][14] - The global competitiveness of Chinese innovative drugs is strengthening, with ongoing internationalization and gradual realization of commercial profits [5][14] ChiNext 50 ETF Overview - The ChiNext 50 ETF (code: 159949) tracks the ChiNext 50 Index, focusing on high-quality leading companies in five key technology sectors: new energy vehicles, biomedicine, electronics, photovoltaics, and internet finance [6][15] - The ETF has a robust liquidity profile, with an average daily trading volume of 1.505 billion yuan over the past year, ranking among the top ETFs on the Shenzhen Stock Exchange [6][15] - The latest fund size is 26.981 billion yuan, making it one of the largest funds tracking the ChiNext-related indices [6][15]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing significant capital inflow, indicating a potential favorable timing for investment in this sector as the innovative drug ETF (520880) shows strong performance despite recent declines [1][3][8]. Group 1: Market Performance - On January 19, the Hong Kong Stock Connect innovative drug ETF (520880) fell by 2.72%, marking three consecutive days of decline, yet recorded a net subscription of 85.51 million yuan, the highest single-day inflow in nearly a month [1][8]. - The latest fund size of the innovative drug ETF reached 2.296 billion yuan, maintaining a historical high with a total of 4.25 billion shares [4][11]. Group 2: Investment Opportunities - Short-term prospects for leading pharmaceutical companies are promising, with 2025 earnings forecasts potentially exceeding expectations, which could lead to valuation recovery opportunities [3][10]. - The first quarter is typically a peak period for overseas licensing transactions, making innovative drug companies with pipeline value, such as those with ADC, bispecific antibodies, and small RNA platforms, worthy of attention [3][10]. Group 3: Long-term Sector Logic - The core logic of the Hong Kong Stock Connect innovative drug sector remains robust, with expected overseas licensing totals for innovative drugs reaching 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][10]. - Continued policy support is anticipated, with the National Medical Products Administration (NMPA) expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the drug review and approval process [3][10]. Group 4: ETF Characteristics - The innovative drug ETF (520880) exclusively invests in innovative drug R&D companies, with over 73% of the top ten holdings representing leading firms in the sector, indicating a strong core strength [5][12][14]. - The ETF is designed to manage risks effectively by reducing the weight of less liquid component stocks, thereby controlling tail risks [6][13].

Core Viewpoint - The article emphasizes the optimistic outlook for China's economy and capital markets in 2026, with international investment banks recommending increased allocations to A-shares and Hong Kong stocks, reflecting confidence in China's economic transformation and growth prospects [1][2]. Group 1: Market Outlook - Goldman Sachs suggests overweighting A-shares and Hong Kong stocks in 2026, while JPMorgan has upgraded the rating for mainland China and Hong Kong stock markets to "overweight" [1]. - UBS believes that policy support, improved corporate earnings, and capital inflows could drive A-share valuations higher [1]. - The 2025 performance of the Hong Kong stock market is described as a significant upward trend, with expectations for continued direction-finding amidst internal and external variables in 2026 [1][3]. Group 2: Investment Strategy - The focus for 2026 should be on two macro variables: the direction of the Federal Reserve's policies and the structural characteristics of the US and Chinese economies [2][3]. - Investment opportunities are seen in sectors such as outbound investments, innovative pharmaceuticals, and AI combined with high-end manufacturing [2][7]. - The consumption market is experiencing a K-shaped recovery, with a preference for investing in leading companies in the discretionary consumption segment [2][7]. Group 3: Competitive Landscape - The article highlights the importance of company competitiveness and the ability to create shareholder value as fundamental to long-term investment success [2][3]. - The performance of high-quality Chinese companies is identified as a solid foundation for the bull market, supported by macroeconomic fundamentals [3]. - The Hong Kong stock market is viewed as a bridge for overseas capital to invest in China, with a growing number of top Chinese companies choosing to list there [5][6]. Group 4: Valuation and Allocation - The overall Hong Kong stock market is considered to be "good value for money," with Chinese assets still in an "under-allocation" phase compared to their global counterparts [6][1]. - The MSCI China Index, which has a significant representation of Hong Kong stocks, is noted to have a lower valuation compared to the MSCI Global Emerging Markets Index, despite a higher return on equity [6][1]. - The article suggests that the low representation of Chinese assets in global indices indicates significant potential for future revaluation [6][1]. Group 5: IPO Market and Stock Selection - The article discusses the active IPO market in Hong Kong, with a notable increase in the number of listings, reflecting the market's role as a global financial center [5][4]. - The focus on identifying high-quality stocks, particularly in the small and mid-cap segments, is emphasized, with a need for deep research to uncover potential investment opportunities [8][9]. - The investment strategy includes avoiding high-valuation companies with low probability of achieving growth and those facing significant innovation challenges [9].

Core Viewpoint - The A-share listed companies are entering a rapid disclosure period for their 2025 annual performance forecasts, with a notable influence from AI and rising commodity prices on company performance [1][2]. Group 1: Performance Forecasts - A total of 451 A-share listed companies have disclosed their 2025 performance forecasts, with 156 companies expecting positive results [1]. - Among these, 42 companies anticipate a net profit growth of over 100% year-on-year [2]. - Notable companies include DingTong Technology, which expects a revenue of approximately 1.593 billion yuan, a 54.37% increase, and a net profit of about 242 million yuan, a 119.59% increase, driven by AI demand in the communications sector [2]. Group 2: Mining Sector Performance - Mining companies are experiencing significant growth due to rising prices and production volumes of gold and copper [3]. - Luoyang Molybdenum Co. expects a net profit of 20 billion to 20.8 billion yuan, a year-on-year increase of 47.8% to 53.71%, attributed to effective cost control and increased product prices [3][4]. - Zijin Mining anticipates a net profit of approximately 51 billion to 52 billion yuan, a growth of 59% to 62%, with increased production of gold and copper [4]. Group 3: Innovation and Emerging Sectors - Companies in semiconductor, innovative pharmaceuticals, and commercial aerospace sectors are gaining market attention, with many receiving intensive institutional research following their performance forecasts [4][5]. - Haopeng Technology expects a net profit of about 19.5 million to 22 million yuan, a growth of 113.69% to 141.09%, driven by advancements in AI hardware applications [5]. - The pharmaceutical industry is entering a critical phase of innovation and global expansion, with investment opportunities focusing on companies with global competitiveness [5].

Core Viewpoint - The Chinese innovative drug sector is experiencing rapid growth, positioning itself as a global leader in drug development, with significant investments and collaborations from major pharmaceutical companies [2][8][30]. Group 1: Market Dynamics - The price of experimental monkeys has surged from 3,000 yuan to 100,000 yuan, indicating a high demand in the innovative drug sector [1]. - By 2025, China is projected to rank second globally in new drug clinical trials, with its pipeline accounting for 30% of the global total [2]. - In 2024, Chinese innovative drug companies completed 94 overseas licensing transactions, representing 44% of the national total, with over 100 transactions exceeding $100 billion in the first ten months of 2025 [6][30]. Group 2: Challenges in Traditional Pharmaceutical Sector - The generic drug sector is facing significant challenges, with a projected 5.5% decline in revenue for 2024 and over 30% of companies experiencing losses [5]. - Major pharmaceutical companies are increasingly collaborating with Chinese innovative drug firms to mitigate the risks associated with patent expirations, which could lead to a revenue gap exceeding $300 billion in the next five years [10][30]. Group 3: Advantages of Chinese Innovative Drugs - China offers a cost-effective and efficient environment for drug development, with clinical trial costs significantly lower than in the U.S. [20][21]. - The average time for clinical trial approvals in China has been reduced from 60 to 30 working days, and the average new drug application approval time has decreased to approximately 130 days [14]. - Chinese pharmaceutical companies are increasingly moving from "me-too" and "me-better" drugs to original innovations, with a notable increase in the number of innovative drug projects [27]. Group 4: Global Positioning and Future Outlook - Despite the rapid growth of Chinese innovative drugs, the overall market value of Chinese biotech companies remains significantly lower than their U.S. counterparts, capturing only 5% to 10% of global new drug revenues [30][31]. - Chinese companies are establishing commercial centers in global pharmaceutical hubs to enhance their commercialization capabilities, marking a shift towards becoming major players in the global market [37][38]. - The transition from biotech firms to large multinational pharmaceutical companies is seen as a critical step in the global battle for market share and innovation [38].

Core Viewpoint - The collaboration between Guangdong Zhongsheng Pharmaceutical Co., Ltd. and Qilu Pharmaceutical marks a significant step in the domestic innovative drug sector, with the potential to help Zhongsheng Pharmaceutical overcome challenges in its traditional business and accelerate its innovative drug development [1][2]. Group 1: Collaboration Details - Zhongsheng Ruichuang retains all rights to the licensed intellectual property and will be the marketing authorization holder after regulatory approval [2]. - The total payment under the agreement can reach 1 billion RMB, including an upfront payment of 200 million RMB and milestone payments up to 800 million RMB, along with a double-digit sales commission after the product launch [2][5]. - This agreement is seen as a crucial move for Zhongsheng Pharmaceutical to enhance its innovative drug platform and commercialize new drugs effectively [2]. Group 2: Financial Performance and Challenges - Zhongsheng Pharmaceutical's traditional business has faced significant pressure due to policies like centralized procurement, with a reported revenue decline of 5.25% in traditional Chinese medicine to 1.318 billion RMB in 2024, and a net loss of 299 million RMB [3]. - Despite a recovery in the third quarter of 2025 with a net profit of 251 million RMB, the company recognizes the need to transform into an innovative pharmaceutical enterprise to break through growth bottlenecks [3]. Group 3: Innovative Drug Development - Zhongsheng Ruichuang, established in 2018, is the core platform for innovative drug research and has successfully brought two innovative drugs to market, with seven additional projects in clinical trials [4]. - The funding from this collaboration will alleviate financial pressure on innovative drug development, supporting ongoing clinical trials for RAY1225 [5]. Group 4: Competitive Landscape - The GLP-1 drug market is becoming increasingly competitive, with both international and domestic companies intensifying their efforts [6]. - RAY1225's advantages include convenient dosing and safety, with a bi-weekly injection schedule that may enhance patient compliance, although its development progress is not leading compared to competitors [7].

智通财经记者 | 黄华 1月上旬，据港交所信披，浙江博锐生物制药股份有限公司（文中简称"博锐生物"）已提交上市申请， 联席保荐人为华泰国际和摩根大通。 博锐生物在医药行业小有名气，它由老牌药企海正药业孵化，前身是海正药业的生物制剂业务部门，于 2019年1月起重组为有限公司。据招股书披露，PAG Highlander（太盟投资集团）及海正药业直接持股 44.62%、39.62%。 在2022年1月接受《21世纪经济报道》专访时，博锐生物时任首席执行官（CEO）王海彬表示，希望企 业会在未来成为全球性的免疫疾病领域龙头。就现阶段而言，博锐生物有不少自免药物，也确实是自 免"大药"阿达木单抗生物类似药的销冠，但距离全球龙头目标尚远，尤其是企业在创新药和国际化方面 只能说是刚刚起步。 1月7日，就博锐生物的IPO动态，智通财经向企业发送了采访邮件。截至发稿时，尚未收到回复。 是阿达木单抗国内销冠 博锐生物是国内隐形的生物药大户，代表产品为阿达木单抗（商品名：安健宁®）。 阿达木单抗是艾伯维公司开发的自免领域生物药，曾11年蝉联全球药王。凭借难以超越的商业成就，原 研商品名修美乐几乎能和药王画上等号。该产品于2003 ...

Group 1 - The core viewpoint of the article highlights a significant increase in trading volume for major broad-based ETFs, specifically the Huatai-PB CSI 300 ETF and the Southern CSI 500 ETF, on January 19 [1][3][5] - During the period from January 14 to 16, stock ETFs (excluding cross-border ETFs) experienced a net outflow of 163.54 billion yuan, with broad-based ETFs alone seeing a net outflow of 198.48 billion yuan [9] - Despite the outflows, the new fund issuance market remains active, with some funds announcing early closure of fundraising due to high demand [12] Group 2 - The Huatai-PB CSI 300 ETF recorded a trading volume of 138 billion yuan on January 19, with notable spikes in trading activity during specific time frames [3] - The Southern CSI 500 ETF also showed significant trading volume, reaching 127 billion yuan for the day, indicating a similar trend to the Huatai-PB CSI 300 ETF [5] - Other ETFs, such as the Huatai-PB CSI A500 ETF and the Huaxia CSI A500 ETF, also exceeded 100 billion yuan in trading volume, reflecting a broader trend in the market [7] Group 3 - Certain thematic ETFs, such as the Harvest Software ETF and the Southern Nonferrous Metals ETF, attracted significant inflows, indicating a divergence in investor interest within the ETF market [10] - The market outlook suggests increased volatility in 2026, but structural opportunities remain significant, particularly in sectors like AI, solid-state batteries, robotics, and innovative pharmaceuticals [13]

Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report emphasizes the continuous catalysts in the small nucleic acid industry for 2026, highlighting the potential investment opportunities within the industry chain [5][19] - The report suggests a positive outlook for innovative drugs and the industry chain, with expectations of increased global participation from domestic innovative drug companies and the introduction of more innovative projects in 2026 [11][30] - The report identifies the medical device sector as a potential area for capital inflow, with signs of improvement in leading companies and a reduction in the pressure from centralized procurement [13][34] Summary by Sections Industry Overview - The closing index for the industry is at 8657.19, with a 52-week high of 9323.49 and a low of 6876.88 [2] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 0.68% from January 12 to January 16, 2026, underperforming the CSI 300 index by 0.11 percentage points [9][28] - The medical research outsourcing sector performed the best among sub-sectors, rising by 3.69%, while the vaccine sector declined by 3.43% [10][28] Innovative Drugs and Industry Chain - The JPM conference highlighted the strengthening of industry development logic, with increased merger and acquisition activity among multinational corporations and breakthroughs in domestic innovative drugs [11][30] - The report recommends focusing on companies with high certainty and relatively low disruption expectations, such as Innovent Biologics and others [11][30] Medical Devices - The report notes that the medical device sector is showing signs of improvement, with leading companies reporting better performance in Q3 [13][34] - The report suggests that the pressure from centralized procurement is decreasing, which may lead to valuation recovery [13][34] Small Nucleic Acid Drugs - The report highlights several key clinical trials and data readouts expected in 2026 from companies like Alnylam, Arrowhead, and Wave Life Sciences, indicating a significant focus on the weight loss and CNS fields [6][8][27] - The report encourages attention to domestic small nucleic acid-related companies and upstream industry chains [27] Investment Recommendations - The report suggests focusing on companies in the CXO and life science services sectors, as demand for overseas R&D and production outsourcing is expected to recover steadily [12][31] - It also highlights the potential for valuation re-evaluation opportunities in the biopharmaceutical sector, particularly for blood products and vaccines [32][33]